Distribution and Analysis of Metastatic Lymph Nodes in Colorectal Cancer Patients (DIAMOND)

NCT ID: NCT07306390

Last Updated: 2025-12-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

1200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2026-01-01

Study Completion Date

2028-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this observational study is to learn about the spatial distribution and significance of metastatic lymph nodes in colorectal cancer patients. The main question it aims to answer is:

* What is the spatial distribution pattern of metastatic lymph nodes in patients with colorectal cancer?
* Can the spatial distribution pattern of metastatic lymph nodes in patients with colorectal cancer guide clinical practice? Participants should undergo regular follow-up examinations for at least 5 years after the surgery.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colon Cancer Rectal Cancer

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Colorectal Cancer Lymph Node Metastasis Spatial Distribution

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Colorectal Cancer Patients

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged between 18 and 80 years
* Pathologically confirmed adenocarcinoma of the colon or rectum
* Underwent radical resection for colorectal cancer with a D3 lymphadenectomy and lymph nodes were submitted for pathological examination according to standardized station-based and distance-based protocol
* No distant metastasis or distant metastasis within 6 months after surgery
* No history of other malignant tumors or severe systemic diseases
* No immune diseases or inflammatory bowel diseases
* Non-emergency surgery
* With complete clinicopathological and follow-up data

Exclusion Criteria

* Pathologically confirmed benign tumors or non-adenocarcinoma malignancies
* Underwent local excision or palliative resection
* Regional lymph nodes were not dissected or submitted for pathological examination according to the unified station-based or distance-based protocol
* With distant metastasis or distant metastasis within 6 months after surgery
* Dual or multiple primary colorectal cancers or concurrent other malignant tumors
* Had a previous diagnosis of immune diseases or inflammatory bowel disease such as ulcerative colitis or Crohn's disease
* Underwent emergency surgery
* Had incomplete clinicopathological or follow-up data
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

China-Japan Friendship Hospital

OTHER

Sponsor Role collaborator

Shanxi Province Cancer Hospital

OTHER

Sponsor Role collaborator

The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital

UNKNOWN

Sponsor Role collaborator

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

HAI ZENG ZHAGN

Medical Doctor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Haizeng Zhang, Doctorate

Role: STUDY_CHAIR

National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences

Beijing, , China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Haizeng Zhang, Doctorate

Role: CONTACT

Phone: +8613511003686

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Haizeng Zhang, Doctorate

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

25/631-5577

Identifier Type: -

Identifier Source: org_study_id